Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
In ELECTRON trial, 100% of hard-to-treat patients cured with sofosbuvir/ledipasvir plus ribavirin or GS-9669

Interferon-free regimens of sofosbuvir and ledipasvir plus either ribavirin or GS-9669 taken for 12 weeks produced sustained response in 100% of treatment-experienced people with genotype 1 chronic hepatitis

Published
04 November 2013
By
Liz Highleyman
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation

In a study conducted among pre-transplant HCV patients (Study 2025), up to 48 weeks of sofosbuvir/RBV therapy was administered. Among patients with undetectable HCV (<25 IU/mL) at the time of transplantation, 64 percent (n=25/39) achieved undetectable HCV RNA 12 weeks post-transplant (pTVR12).

Published
03 November 2013
From
Gilead press release
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients

In the Phase 3 VALENCE study, 85 percent (n=212/250) of treatment-naïve or treatment-experienced patients with genotype 3 HCV who received a 24-week regimen of sofosbuvir plus ribavirin (RBV) achieved a sustained virologic response 12 weeks after treatment (SVR12). Patients who achieve SVR12 are considered cured of HCV infection.

Published
03 November 2013
From
Gilead press release
Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data

High rate of virologic response in Phase II hepatitis C trial of a 12 week all-oral combination of Boehringer Ingelheim’s faldaprevir* and deleobuvir* and Presidio’s PPI-668* with and without ribavirin.

Published
03 November 2013
From
Boehringer Ingelheim
High cure rates seen with Merck oral hepatitis drugs - study

A combination of two oral hepatitis C treatments developed by Merck & Co led to high cure rates in previously untreated patients, indicating the company is a contender in the race to find new treatments for the liver destroying virus.

Published
03 November 2013
From
Reuters
Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant

New drug therapies offer promise to some hepatitis C sufferers whose transplanted livers are threaten by a recurrence of the disease, including some patients who have had no treatment options.

Published
01 November 2013
From
Eurekalert Medicine & Health
Studies: Current hepatitis C treatments can't be used by more than half of patients; others lose opportunity for treatment

More than half of chronic hepatitis C patients studied in a new research project led by Henry Ford Hospital were not treated for the potentially fatal disease, either because they couldn't withstand current therapies or because they, or their doctors, were waiting for new treatments.In a second, related study, Henry Ford researchers found that while the disease is not yet curable, there is a significant "lost opportunity" for hepatitis C patients to achieve the current best result of treatment.

Published
01 November 2013
From
Eurekalert Medicine & Health
Idenix provides HCV pipeline update

Enrollment initiated for a phase I /II clinical trial for IDX21437, a next-generation uridine nucleotide prodrug inhibitor for the treatment of hepatitis C virus infection (HCV); initiation planned for HELIX - 2 combination study in collaboration with Janssen Pharmaceuticals, Inc. including pan-genotypic HCV NS5A inhibitor, samatasvir.

Published
01 November 2013
From
Idenix press release
Gay Men Should Be Tested for Hepatitis C

Dr Lawrence Mass, a co-founder of GMHC, calls for explicit US public health recommendations on hepatitis C testing for sexually active gay men.

Published
31 October 2013
From
Huffington Post (blog)
UNITAID publishes first scoping report on hepatitis C

UNITAID has published its first effort to gather market intelligence on products for the diagnosis and treatment of Hepatitis C, one of the leading co-infections for people living with HIV. UNITAID’s scoping report [PDF, 900 KB] gives an overview of this viral disease, as well as existing and pipeline medicines and diagnostics, commodity access issues and market shortcomings.

Published
30 October 2013
From
UNITAID

Filter by country